BUZZ-摩根大通将蓝鸟生物的评级提升至 "中性"。

路透中文
24 Feb
BUZZ-<a href="https://laohu8.com/S/JPM">摩根大通</a>将蓝鸟生物的评级提升至 "中性"。

2月24日 - ** 摩根大通将基因治疗公司蓝鸟生物BLUE.O的评级从 "减持 "上调至 "中性",理由是该公司宣布将被私有化。

** 券商预计该公司的私有化将在下半年进行

** BLUE 称将被凯雷CG.O和 SK Capital Partners私有化 (link)

** 8家券商中有1家将BLUE股票评级为 "买入",7家为 "持有";他们的PT中值为10美元 - LSEG数据

** 截至上一交易日收盘,股价累计下跌约 51.1

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10